Investor Relations

About
Pipeline
- Overview
- SNS-301
- SNS-401
- Vista
- Presentations
Platform
Our Leadership
Careers
Investors and Media

Contact

Investor Relations

About
Pipeline
- Overview
- SNS-301
- SNS-401
- Vista
- Presentations
Platform
Our Leadership
Careers
Investors and Media

Contact Us

Investor Contact:

Julie Seidel | Courtney Turiano
Stern Investor Relations, Inc.
ir@senseibio.com

Name

Email

Subject

Comments

Leave this field blank

Investor Tools

Email Alerts
Investor FAQs
RSS Feeds
Contact Us

About

We are biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. We have developed two unique approaches – a TMAb™ (Tumor Microenvironment Activated biologics) platform, comprising unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment, and an ImmunoPhage™ platform that leverages bacteriophage to fully engage the immune system. Using our TMAb platform, we developed SNS-101, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). Using the ImmunoPhage platform, we are developing a library of ImmunoPhage, called Phortress™, with multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. This platform is designed to enable efficient, scalable and cost-effective manufacturing to support our clinical programs. SNS-401-NG is a next generation ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma.

Contact

Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850

Phone No

+1.240.243.8000

Boston R&D Location
451 D Street, Suite 710
Boston, MA 02210

Email

info@senseibio.com

Legal

Privacy Policy

Social Links

Go to Top